Edwards Lifesciences Corp (EW) : Dixon Hubard Feinour Brown Incva added new position in Edwards Lifesciences Corp during the Fourth Quarter. The investment management firm now holds 65,074 shares of Edwards Lifesciences Corp which is valued at $5.6 Million according to most recent disclosure to SEC.Edwards Lifesciences Corp makes up approximately 1.78% of Dixon Hubard Feinour Brown Incva’s portfolio.
Other Hedge Funds, Including , Pier Capital boosted its stake in EW during the Q4 period, The investment management firm added 139 additional shares and now holds a total of 8,293 shares of Edwards Lifesciences Corp which is valued at $711,622. Edwards Lifesciences Corp makes up approx 0.13% of Pier Capital’s portfolio.Sawtooth Asset Management boosted its stake in EW during the Q4 period, The investment management firm added 429 additional shares and now holds a total of 745 shares of Edwards Lifesciences Corp which is valued at $63,928. Edwards Lifesciences Corp makes up approx 0.01% of Sawtooth Asset Management’s portfolio.Tributary Capital Management reduced its stake in EW by selling 3,000 shares or 9.74% during the fourth quarter. The Hedge Fund company now holds 27,800 shares of EW which is valued at $2.4 Million. Edwards Lifesciences Corp makes up approx 0.39% of Tributary Capital Management’s portfolio.Commonwealth Of Pennsylvania Public School Empls Retrmt Sys boosted its stake in EW during the Q4 period, The investment management firm added 278 additional shares and now holds a total of 14,094 shares of Edwards Lifesciences Corp which is valued at $1.2 Million. Edwards Lifesciences Corp makes up approx 0.03% of Commonwealth Of Pennsylvania Public School Empls Retrmt Sys’s portfolio. Brave Asset Management Inc added EW to its portfolio by purchasing 400 company shares during the Fourth Quarter which is valued at $34,324. Edwards Lifesciences Corp makes up approx 0.02% of Brave Asset Management Inc’s portfolio.
On the company’s financial health, Edwards Lifesciences Corp reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.60. The company had revenue of $671.10 million for the quarter, compared to analysts expectations of $651.30 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS.
Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Edwards Lifesciences Corp was Initiated by Nomura to “Buy” on Mar 17, 2016. Company shares were Reiterated by RBC Capital Mkts on Feb 3, 2016 to “Outperform”, Firm has raised the Price Target to $ 100 from a previous price target of $93 .Company shares were Reiterated by Canaccord Genuity on Feb 3, 2016 to “Buy”, Firm has raised the Price Target to $ 92 from a previous price target of $90 .
Edwards Lifesciences Corp closed down -0.17 points or -0.20% at $85.64 with 10,03,717 shares getting traded on Monday. Post opening the session at $85.57, the shares hit an intraday low of $85.205 and an intraday high of $86.13 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.